• Oral presentation (Proffered paper session): Papachristofilou A. et al, SAKK 01/10: Single-dose carboplatin followed by involved-node radiotherapy as curative treatment for seminoma stage IIA/B: efficacy results from the international multicenter phase II trial SAKK 01/10.

ESMO daily Reporter: De-escalated treatment improves the management of stage IIA/B seminoma.

• Oral presentation (Mini oral): Cathomas R. et al, SAKK 08/16: Darolutamide maintenance in metastatic castration resistant prostate cancer (mCRPC) previously treated with novel hormonal agents (NHA) and non-progressive disease after subsequent treatment with a taxane: A randomized double-blind placebo-controlled phase II trial (SAKK 08/16).

ESMO daily Reporter: Switch maintenance with darolutamide shows promise in previously treated mCRPC. 

• ePoster: Jörger M. et al, SAKK 80/20: Outcome and prognostic factors of COVID-19 infection in cancer patients: Final results of SAKK 80/20 

•  ePoster: Wicki A. et al, SAKK 24/14: Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative, EGFR positive breast cancer - A multicenter single arm phase II trial [SAKK 24/14].